Skip to main content
. 2020 Jul 23;8(2):e000516. doi: 10.1136/jitc-2019-000516

Figure 2.

Figure 2

Prexasertib-induced changes in innate immunity. (A) An increase from pre-treatment to post-treatment percent monocytes per total viable cells observed with flow cytometric analysis of 23 paired PBMC samples using the Wilcoxon matched-pairs signed-rank test. Lines denote median and 95% CI. (B) Survival curves were compared using the Mantel-Cox log-rank test. An increase in HLA-DR on total monocytes, seen in 12 of 23 patients, is associated with improved PFS (9.25 vs 3.5 months, p=0.019). (C) An increase in HLA-DR on classical monocytes, seen in 9 of 23 patients, is associated with improved PFS (9.5 vs 3.75 months, p=0.04). (D) An increase in HLA-DR on non-classical monocytes, seen in 10 of 23 patients, is associated with improved PFS (11.5 vs 4 months, p=0.002). (E) Increased expression of TBK1, a key protein in the STING pathway, seen in six of nine patients with paired pre-treatment and post-treatment biopsies, is associated with improved PFS (9 vs 3 months, p=0.003). HLA-DR, Human Leukocyte Antigen DR antigen; mono, monocytes, mo, months; PBMC, peripheral blood mononuclear cells; PFS, progression-free survival; STING, stimulator of interferon genes; TBK1, TANK-binding kinase 1.